

Org Lett. Author manuscript; available in PMC 2011 February 5.

Published in final edited form as:

Org Lett. 2010 February 5; 12(3): 412. doi:10.1021/ol902433a.


Fully Automated Continuous Flow Synthesis of Highly Functionalized Imidazo[1,2-a] Heterocycles

Ananda Herath, Russell Dahl, and Nicholas D. P. Cosford

Conrad Prebys Center for Chemical Genomics, Burnham Institute for Medical Research 10901 North Torrey Pines Road, La Jolla, CA 92037

Ananda Herath: ; Russell Dahl: ; Nicholas D. P. Cosford: ncosford@burnham.org

Abstract



The first continuous flow synthesis of imidazo[1,2-a]pyridine-2-carboxylic acids directly from 2-aminopyridines and bromopyruvic acid has been developed, representing a significant advance over the corresponding in-flask method. The process was applied to the multistep synthesis of imidazo [1,2-a]pyridine-2-carboxamides, including a Mur ligase inhibitor, using a two microreactor, multistep continuous flow process without isolation of intermediates.

Over the past several years high-throughput chemical synthesis has become increasingly important because of its potential to positively impact the drug discovery process. ¹⁻³ Two of the most common hurdles encountered in the development of high-throughput syntheses of libraries of complex molecules have been slow reaction times and reliance on harsh or inconvenient reaction conditions. Moreover, the optimization and purification of these reactions are often time consuming and inefficient. Automated microreactor-based (microfluidic chip) continuous flow systems have the potential to greatly accelerate the production of small molecule libraries. ^{4,5} Advantages include efficient heat transfer, enhanced reagent mixing, small reaction volumes, and the potential to run multistep reactions in a single, uninterrupted microreactor sequence using continuous flow conditions. ^{6,7} We are developing flow chemistry methods for transformations that are either not possible or highly inefficient using in-flask chemistry. This will enable the rapid synthesis of highly functionalized, druglike small molecules in high purity and on a scale sufficient for evaluation in multiple biological

assays. We previously reported the preparation of 1,2,4-oxadiazoles from arylnitriles and activated carbonyls in a single continuous flow sequence. The now report the efficient, multistep, continuous flow synthesis of diverse, highly functionalized imidazo[1,2-a] heterocycles directly from commercially available starting materials.

The imidazo[1,2-a]heterocyclic scaffold is found in compounds with anticancer, antiviral and antimicrobial activities, and in modulators of the nervous system.^{8, 9} Typically, the synthesis of imidazo[1,2-a]heterocycles requires long reaction times and high temperatures, limiting the accessibility of these biologically important structures.¹⁰ Direct condensation of 2-bromopyruvic acid with 2-aminopyridines to generate imidazo[1,2-a]pyridine-2-carboxylic acids is inefficient due to competing decarboxylation of the product at high temperatures. Therefore, stepwise protocols are generally used for the formation of imidazopyridine carboxylic acid derivatives. For example, in a typical in-flask procedure, ethyl bromopyruvate is condensed with 2-aminopyridine (Scheme 1).

The product ester is isolated and subjected to saponification to provide the product. ¹¹ Naturally, each in-flask step involves work-up and purification of the intermediates. Herein we report the first continuous flow synthesis of imidazo[1,2-a]pyridine-2-carboxylic acids from 2-aminopyridines and bromopyruvic acid using a single microreactor to enable the rapid synthesis of these compounds. We further demonstrate the incorporation of this procedure into a continuous, two microreactor method for the highly efficient preparation of a diverse library of amide derivatives.

Focusing initially on the flow synthesis of imidazo[1,2,a]heterocyclic acids, we screened a variety of substrates and reaction conditions using a single microreactor and found that the use of a catalytic amount of *p*-toluenesulphonic acid (PTSA) (0.25 equiv.) efficiently provided the desired products from 2-aminopyridines (1.0 equiv.) and bromopyruvic acid (1.2 equiv.) in dimethylformamide (DMF) at 125 °C. Although previous in-flask studies reported the use of protic solvents for the synthesis of this class of heterocycles, DMF was selected due to its high boiling point and excellent solubilizing properties. The 2-aminopyridine (0.5 M) and bromopyruvic acid (0.5 M) were introduced into the microreactor and PTSA was either flowed in via a separate channel or pre-mixed with the bromopyruvic acid. Reaction monitoring by LCMS analysis showed that the conversion of bromopyruvic acid to the corresponding imidazo [1,2-a]pyridine-2-carboxylic acid derivative was complete within 10 min in a preheated microreactor at 125 °C and 4.0 bar. Under these conditions a series of imidazo[1,2-a] pyridine-2-carboxylic acids was efficiently synthesized in moderate to high yields (Table 1).

Using the optimized reaction conditions, different 2-aminopyridines were synthesized (Table 1). Reactions of 2-aminopyridines having electron-donating (Table 1, Entry 1) or electron-withdrawing groups (Table 1, Entries 2 and 4) proceeded efficiently with moderate to excellent yields. Notably, functionalized 2-aminopyridines underwent cyclization leading to chloro-(Table 1, Entries 2, 5), bromo-(Table 1, Entry 7), hydroxy- (Table 1, Entry 6), and amino-(Table 1, Entry 5) substituted imidazo[1,2-a]pyridine-2-carboxylic acids. One intriguing observation was that this new method can be used to generate free amine or hydroxyl group-containing imidazopyridine carboxylic acids in an efficient manner, without the need to use protecting groups. The product in Table 1, Entry 4 is notable since it is a dicarboxylic acid that is monoprotected as the ester, allowing selective functionalization of the free acid in subsequent synthetic transformations. Additionally, the new flow method can be applied to the synthesis of other imidazoheterocyclic scaffolds such as pyrimidines (Table 1, Entry 3), thiazoles (Table 1, Entry 8), and benzothiazoles (Table 1, Entry 9). Significantly, the product in Table 1, Entry 9 is a key intermediate for the preparation of AB530, a recently disclosed FLT3 kinase inhibitor under evaluation for the treatment of cancer. Coursel of the provides of the provides the

product in 63% yield constitutes a major improvement over the reported two step, in-flask procedure to afford the product in 22% overall yield.

To demonstrate the utility of the newly developed methodology, our next goal was to develop a continuous flow method to access imidazo[1,2-a]pyridine-2-carboxamides in a single, uninterrupted process directly from readily available starting materials. Optimization studies showed that a combination of EDC/HOBt/DIPEA (1:1:2) for 10 minutes at 75 °C were the best conditions for complete conversion of the imidazoheterocyclic acids to the corresponding amide derivatives. Initial efforts to directly combine these two reactions using two microreactors were unsuccessful. Experimentation with a variety of reaction conditions demonstrated that removal of PTSA from the first reaction and the separate addition of solutions of EDC/HOBt (1:1) and amines/DIPEA (1:1) were necessary to achieve conversion. The major reaction competing with the amidation is the nucleophilic addition of the amine to EDC. Thus, to compensate for this side reaction the amidation reactions were performed using an excess of base and amine. The final optimized conditions employed were: i) 1.2 equivalents of bromopyruvic acid; ii) a residence time on the first microreactor of 20 min and a temperature 100 °C; and iii) the stream containing the imidazo[1,2-a]pyridine-2-carboxylic acid exiting the first microreactor was combined with a solution of EDC/HOBt and amines/DIPEA in a second microreactor at 75 °C for 10 min. (Figure 1).

Several aspects of this new continuous flow process are noteworthy. First, this is the first example of the synthesis of imidazo[1,2-a]heteroaryl-2-carboxamides in a single continuous process, directly from readily available starting materials (i.e. 2-aminopyridines and bromopyruvic acid). As noted previously, the in-flask synthesis of these compounds involves multiple reaction steps involving workup and purification of multiple intermediates, ¹³ often requiring the use of strong Lewis acids. ¹⁴ Second, until now, the accessibility of these amides was limited due to the lack of applicable methodologies to generate various amides using commercially available starting materials. Finally, since this method involves the introduction of amines in the final step, it provides a convenient handle for further derivitization of the products and a wide variety of amides are accessible simply by changing the amines.

This novel continuous flow method tolerates a wide range of amines such as primary (Table 2, Entries 3 and 7-12), secondary (Table 2, Entries 4 and 5), aryl (Table 2, Entry 1), heteroaryl (Table 2, Entry 2) and heterocyclic (Table 2, Entry 5). It is noteworthy that comparatively unreactive 3-aminopyridine couples efficiently (Table 2, Entry 2). Additionally, amino acid derivatives can directly couple efficiently to introduce further complexity to the final products (Table 2, Entry 6). Furthermore, different imidazo[1,2,a]heterocarboxamides such as thiazoles and pyrimidines can be accessed efficiently. Moreover, free amines (Table 2, Entry 9) and free hydroxyl (Table 2, Entry 10) containing amides can be synthesized efficiently. The tolerance of free amine and free hydroxyl groups is particularly noteworthy since previous syntheses of this type of scaffold were initially only achievable in a stepwise manner. Finally, to demonstrate the utility of the new method we synthesized compound 3, a Mur ligase inhibitor with potential antibacterial activity. The in-flask synthesis of this compound was reported to proceed in 16.4% overall yield over two steps. Using our continuous flow method compound 3 was prepared in a single step in 46% yield (Scheme 2).

In summary, we have developed novel continuous flow methods for the synthesis of imidazo [1,2-a]pyridine-2-carboxylic acids and imidazo[1,2-a]pyridine-2-carboxamides using readily available starting materials and standard, commercially available reagents. This work documents the first highly efficient synthesis of imidazo[1,2-a]pyridine-2-carboxylic acids and amides directly from 2-aminopyridines and bromopyruvic acids. Furthermore, the continuous flow nature of our synthesis enables the facile scale-up of these compounds, which is highly advantageous for drug discovery. We anticipate that these advances will facilitate the rapid

synthesis of these biologically important scaffolds. Further exploration of the reactivity features of the process and applications to focused library synthesis of complex biologically active molecules are in progress.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by National Institutes of Health grant nos. HG005033, GM079590 and GM081261.

References

- 1. (a) Chighine A, Sechi G, Bradley M. Drug Discov Today 2007;12:459. [PubMed: 17532530] (b) Kang L, Chung BG, Langer R, Khademhosseini A. Drug Discov Today 2008;13:1. [PubMed: 18190858]
- (a) Schreiber SL. Science 2000;287:1964. [PubMed: 10720315] (b) Nicolaou KC, Zhong YL, Baran PS. Angew Chem Int Ed 2000;39:622. (c) Nicolaou KC, Zhong YL, Baran PS. Angew Chem Int Ed 2000;39:625. (d) Sheehan SM, Lalic G, Chen JS, Shair MD. Angew Chem Int Ed 2000;39:2714. (e) Huryn DM, Cosford NDP. Annu Rep Med Chem 2007;42:401. (f) Dobson CM. Nature 2004;432:824. [PubMed: 15602547] (g) Stockwell BR. Nature 2004;432:846. [PubMed: 15602550] (h) Lipinski C, Hopkins A. Nature 2004;432:855. [PubMed: 15602551]
- 3. (a) Deng Z, Chuaqui C, Singh. J Med Chem 2006;49:490. [PubMed: 16420036] (b) Kirschning A, Monenschein H, Wittenberg R. Angew Chem Int Ed 2001;40:650. (c) Kappe CO, Dallinger D. Nature Rev Drug Discov 2006;5:51. [PubMed: 16374514]
- 4. (a) Griffiths-Jones CM, Hopkin MD, Jönsson D, Ley SV, Tapolczay DJ, Vickerstaffe E, Ladlow M. J Comb Chem 2007;9:422. [PubMed: 17348713] (b) Baxendale IR, Ley SV, Smith CD, Tranmer GK. Chem Commun 2006:4835. (c) Baumann M, Baxendale IR, Ley SV, Nikbin N, Smith CD, Tierney JP. Org Biomol Chem 2008;6:1577. [PubMed: 18421389] (d) Baumann M, Baxendale IR, Ley SV, Nikbin N, Smith CD. Org Biomol Chem 2008;6:1587. [PubMed: 18421390] (e) Brandt JC, Wirth T. Beilstein J Org Chem 2009;5(No 30) (f) Hooper J, Watts P, Wiles C. Microfluidics Nanofluidics 2008;5:595. (g) Baumann M, Baxendale IR, Ley SV, Smith CD, Tranmer GK. Org Lett 2006;8:5231. [PubMed: 17078685] (h) Jas G, Kirschning A. Chem Eur J 2003;9:5708. (i) Kirschning A, Solodenko W, Mennecke K. Chem Eur J 2006;12:5972.
- (a) Mason BP, Price KE, Steinbacher JL, Bogdan AR, McQuade DT. Chem Rev 2007;107:2300. [PubMed: 17373852] (b) Baxendale, IR.; Hayward, JJ.; Lanners, S.; Ley, SV.; Smith, CD. Microreactors in Organic Synthesis and Catalysis. Wirth, T., editor. Wiley-VCH; Weinheim: 2008. (c) Ehrfeld, W.; Hessel, V.; Lowe, H. Microreactors: New Technology for Modern Chemistry. Wiley; Weinheim: 2000. (d) Jähnisch K, Hessel V, Löwe H, Baerns M. Angew Chem Int Ed 2004;43:406. (f) Csajági C, Borcsek B, Niesz K, Kovács I, Székelyhidi Z, Bajkó Z, Ürge L, Darvas F. Org Lett 2008;10:1589. [PubMed: 18358035] (g) Yoshida J, Nagaki A, Yamada T. Chem Eur J 2008;14:7450. (h) Fukuyama T, Kobayashi M, Rahman MT, Kamata N, Ryu I. Org Lett 2008;10:533. [PubMed: 18211074] (i) Kundig P. Science 2006;314:430. [PubMed: 17053137] (j) Carrel FR, Geyer K, Codee JD, Seeberger PH. Org Lett 2007;9:2285. [PubMed: 17489597] (j) Watts P, Wiles C. Chem Commun 2007:443. (k) Watts P, Wiles C. Org Biomol Chem 2007;5:727. [PubMed: 17315057]
- (a) Lee CC, Sui G, Elizarov A, Shu CJ, Shin Y, Dooley AN, Huang J, Daridon A, Wyatt P, Stout D, Kolb HC, Witte ON, Satyamurthy N, Heath JR, Phelps ME, Quake SR, Tseng H. Science 2005;310:1793. [PubMed: 16357255] (b) Gustafsson T, Gilmour R, Seeberger PH. Chem Commun 2008:3022. (c) Gustafsson T, Ponten F, Seeberger PH. Chem Commun 2008:1100. (d) Lu S, Clements JT, Gilde MJ, Prak A, Watts P, Pike VW. J Labelled Comp Radiopharm 2007;50:597.
- 7. (a) Grant D, Dahl R, Cosford NDP. J Org Chem 2008;73:7219. [PubMed: 18687005] (b) Baxendale IR, Ley SV, Mansfield AC, Smith CD. Angew Chem Int Ed 2009;48:4017. (c) Usutani H, Tomida Y, Nagaki A, Okamoto H, Nokami T, Yoshida J. J Am Chem Soc 2007;129:3046. [PubMed: 17323950] (d) Sahoo HR, Kralj JG, Jensen KF. Angew Chem Int Ed 2007;46:5704. (e) Schwalbe T, Autze V, Wille G. Chimia 2002;56:636. (f) Watts P, Wiles C, Haswell SJ, Pombo-Villar E. Tetrahedron 2002;58:5427.

8. (a) Hamdouchi C, Blas J, Prado M, Gruber J, Heinz BA, Vance L. J Med Chem 1999;42:50. [PubMed: 9888832] (b) Hamdouchi C, Blas J, Prado M, Gruber J, Heinz BA, Vance L. J Med Chem 1999;42:50. [PubMed: 9888832] (c) Gueiffier A, Mavel S, Lhassani M, Elhakmaoui A, Snoeck R, Andrei G, Chavignon O, Teulade J, Witvrouw M, Balzarini J, Clercq E, Chapat J. J Med Chem 1998;41:5108. [PubMed: 9836626] (d) Starr JT, Sciotti RJ, Hanna DL, Huband MD, Mullins LM, Cai H, Gage JW, Lockard M, Rauckhorst MR, Owen RM, Lall MS, Tomilo M, Chen H, McCurdy SP, Barbachyn MR. Bioorg Med Chem Lett 2009;19:5302. [PubMed: 19683922]

- (a) Enguehard-Gueiffier C, Hübner H, Hakmaoui AE, Allouchi H, Gmeiner P, Argiolas A, Melis MR, Gueiffier A. J Med Chem 2006;49:3938. [PubMed: 16789750] (b) Mattner F, Mardon K, Loc'h C, Katsifis A. Life Sci 2006;79:287. [PubMed: 16464478] (c) Kercher T, Rao C, Bencsik JR, Josey JA. J Comb Chem 2007;9:1177. [PubMed: 17824665] (d) Selleri S, Bruni F, Costagli C, Costanzo A, Guerrini G, Ciciani G, Gratteri P, Besnard F, Costa B, Montali M, Martini C, Fohlin J, Siena G, Aiello PM. J Med Chem 2005;48:6756. [PubMed: 16220991] (e) Almirante L, Polo L, Mugnaini A, Provinciali E, Rugarli P, Biancotti A, Gamba A, Murmann WJ. J Med Chem 1965;8:305. [PubMed: 14329509]
- 10. (a) Katritzky AR, Qiu G, Long Q, He H, Steel PJ. J Org Chem 2000;65:9201. [PubMed: 11149870](b) Katritzky AR, Xu YJ, Tu H. J Org Chem 2003;68:4935. [PubMed: 12790603]
- 11. (a) Ager IR, Barnes AC, Danswan GW, Hairsine PW, Kay DP, Kennewell PD, Matharu SS, Miller P, Robson P, Rowlands DA, Tully WR, Westwood R. J Med Chem 1988;31:1098. [PubMed: 2897466] (b) Kaizerman JA, Gross MI, Ge Y, White S, Hu W, Duan J, Baird EE, Johnson KW, Tanaka RD, Moser HE, Bürli RW. J Med Chem 2003;46:3944. (c) Varvaresou A, Tsotinis A, Siatra-Papastaikoudi T, Papadaki-Valiraki A, Thurston DE, Jenkins TC, Kelland LR. Bioorg Med Chem Lett 1996;6:865.
- Patel HK, Grotzfeld RM, Lai AG, Mehta SA, Milanov ZV, Chao Q, Sprankle KG, Carter TA, Velasco AM, Fabian MA, James J, Treiber DK, Lockhart DJ, Zarrinkar PP, Bhagwat SS. Bioorg Med Chem Lett 2009;19:5182–5185. [PubMed: 19646870]
- 13. Warshakoon NC, Wu S, Boyer A, Kawamoto R, Sheville J, Renock S, Xu K, Pokross M, Evdokimov AG, Walter R, Mekel M. Bioorg Med Chem Lett 2006;16:5598. [PubMed: 16962772]
- 14. Masurier N, Moreau E, Lartigue C, Gaumet V, Chezal J, Heitz A, Teulade J, Chavignon O. J Org Chem 2008;73:5989. [PubMed: 18597528]
- 15. Abe Y, Kayakiri H, Satoh S, Inoue T, Sawada Y, Imai K, Inamura N, Asano M, Hatori C, Katayama A, Oku T, Tanaka H. J Med Chem 1998;41:564. [PubMed: 9484506]
- Groselj U, Bezensek J, Meden A, Svete J, Stanovnik B, Oblak M, Anderluh PS, Urleb U. Heterocycles 2008;75:1355.




Figure 1. Continuous flow sequence for the synthesis of imidazo[1,2-a]pyridine-2-carboxamides.

Scheme 1.

In-flask preparation of imidazo[1,2-a]pyridine-2-carboxylic acids and imidazo[1,2-a] pyridine-2-carboxamides.

Scheme 2. Continuous flow preparation of Mur ligase inhibitor 3.

Table 1

Flow synthesis of imidazo[1,2-a]pyridine-2-carboxylic acids.

entry	product	yield (
1	Me N CO ₂ H	72
2		71
3		60

product entry yield (%) 4 68 5 65 6 52 72

entry	product	yield (%)
8	$S \setminus N$ CO_2H	68
9	S N CO ₂ H	63

 $^{{}^{}a}\text{Isolated yield based on }\textbf{1}\text{ after purification of crude reaction mixture using preparative HPLC. Reactions were performed on }0.45\text{ mmol scale.}$

 $\label{eq:Table 2} \textbf{Table 2}$ Direct multistep synthesis of imidazo[1,2-a]pyridine-2-carboxamides from 1 and 2.

product yield (%)^a entry 2

entry product yield $(\%)^a$

entry product yield $(\%)^a$

entry product yield (%)^a 9 10

entry	product yield $(\%)^a$
11	
12	\$\tag{\text{N} \times \text{N}

 $[^]a$ Isolated yield based on 1 after purification of crude reaction mixture using preparative HPLC. Reactions were performed on 0.38 mmol scale.